Related Experiment Video
Updated: Aug 3, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Is Aspiration Thrombectomy Beneficial in Patients Undergoing Primary Percutaneous Coronary Intervention?
Islam Y Elgendy1, Tianyao Huo1, Deepak L Bhatt1
1From the Department of Medicine, University of Florida, Gainesville (I.Y.E., T.H., A.A.B.); Department of Medicine, Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); and Medicine Service, North Florida/South Georgia Veterans Health System, Gainesville (A.A.B.).
Insights
Aspiration thrombectomy before primary percutaneous coronary intervention (PCI) offers no clinical benefit for ST-segment-elevation myocardial infarction patients and may increase stroke risk. Glycoprotein IIb/IIIa inhibitors and ischemic time did not alter these outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Uncertainty exists regarding the impact of intravenous glycoprotein IIb/IIIa inhibitors and ischemic time on the efficacy of aspiration thrombectomy preceding primary percutaneous coronary intervention (PCI) in ST-segment-elevation myocardial infarction (STEMI) patients.
- Aspiration thrombectomy is a procedure to remove blood clots from coronary arteries.
Purpose of the Study:
- To evaluate the clinical benefits and risks of aspiration thrombectomy before primary PCI in STEMI patients.
- To investigate whether intravenous glycoprotein IIb/IIIa inhibitors or ischemic time modify the clinical outcomes of aspiration thrombectomy.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials comparing aspiration thrombectomy followed by primary PCI versus conventional primary PCI in STEMI patients.
- Seventeen trials involving 20,960 patients were analyzed using a DerSimonian-Laird model to calculate summary estimates.
Main Results:
- Aspiration thrombectomy did not significantly reduce the risk of mortality (2.8% vs 3.2%), reinfarction (1.3% vs 1.4%), or the combined outcome of mortality or reinfarction (4.1% vs 4.6%) compared to conventional PCI.
- The procedure was associated with a nonsignificant increase in stroke risk (0.6% vs 0.4%).
- Meta-regression analysis revealed no significant influence of intravenous glycoprotein IIb/IIIa inhibitors or ischemic time on the observed outcomes.
Conclusions:
- Aspiration thrombectomy before primary PCI is not associated with improved clinical end points in STEMI patients.
- The procedure may potentially increase the risk of stroke.
- Concomitant use of glycoprotein IIb/IIIa inhibitors and varying ischemic times did not appear to modify the clinical benefits of aspiration thrombectomy.
Background:
It is unclear whether intravenous glycoprotein IIb/IIIa inhibitors or ischemic time might modify any clinical benefits observed with aspiration thrombectomy before primary percutaneous coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction.
Methods And Results:
Electronic databases were searched for trials that randomized ST-segment-elevation myocardial infarction patients to aspiration thrombectomy before PCI versus conventional PCI. Summary estimates were constructed using a DerSimonian-Laird model. Seventeen trials with 20 960 patients were available for analysis. When compared with conventional PCI, aspiration thrombectomy was not associated with a significant reduction in the risk of mortality 2.8% versus 3.2% (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.76-1.04; P=0.13), reinfarction 1.3% versus 1.4% (RR, 0.93; 95% CI, 0.73-1.17; P=0.52), the combined outcome of mortality or reinfarction 4.1% versus 4.6% (RR, 0.90; 95% CI, 0.79-1.02; P=0.11), or stent thrombosis 0.9% versus 1.2% (RR, 0.82; 95% CI, 0.62-1.08; P=0.15). Aspiration thrombectomy was associated with a nonsignificant increase in the risk of stroke 0.6% versus 0.4% (RR, 1.45; 95% CI, 0.96-2.21; P=0.08). Meta-regression analysis did not identify a difference for the log RR of mortality, reinfarction, and the combined outcome of mortality or reinfarction with intravenous glycoprotein IIb/IIIa inhibitors (P=0.17, 0.70, and 0.50, respectively) or with ischemic time (P=0.29, 0.66, and 0.58, respectively).
Conclusions:
Aspiration thrombectomy before primary PCI is not associated with any benefit on clinical end points and might increase the risk of stroke. Concomitant administration of intravenous glycoprotein IIb/IIIa inhibitors and ischemic time did not seem to influence any potential benefits observed with aspiration thrombectomy.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

